GNFT

Elafibranor

Non-alcoholic steatohepatitis (NASH)

Stage (next event)

Expected Date

Discontinued

Discontinued

Catalyst Info & Data Links

MECHANISM OF ACTION / RATIONALE

  • Elafibranor is a dual agonist of the PPARα and PPARδ. Meaning the drug candidate acts simultaneously on the two nuclear receptors, which both play an important role in numerous processes involved in the development of NASH and its co-morbidities (learn more)

COMPETITORS

  • Cenicriviroc - Allergan

  • Cotadutide - AstraZeneca

  • Ocaliva - Intercept Pharmaceuticals

  • Resmetirom - Madrigal Pharmaceuticals

  • Selonsertib - Gilead

  • Tropifexor - Novartis

MARKET

  • ~19 million NASH patients

  • ~16 million  patients with fibrosis due to NASH

  • ~1.5M under Hep/GI care



Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon